Zelminemab

Modify Date: 2024-01-10 20:09:36

Zelminemab structure	Common Name	Zelminemab
	CAS Number	2225850-33-7	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Zelminemab

Zelminemab (AMG-301) is a human monoclonal antibody that inhibits PACAP type I (PAC1) receptor[1].

Name	Zelminemab

Description	Zelminemab (AMG-301) is a human monoclonal antibody that inhibits PACAP type I (PAC1) receptor[1].
Related Catalog	Signaling Pathways >> GPCR/G Protein >> Adenylate Cyclase Research Areas >> Neurological Disease
In Vivo	Zelminemab（10 mg/kg；i.v.；一次）降低 TCC 中的伤害性神经元活动[2]。 Animal Model: Sprague-Dawley rats, electricalstimulation was performed on the intact dura mater abovethe middle meningeal artery[2]. Dosage: 10 mg/kg Administration: i.v.; once Result: Induced an inhibition of stimulus-evoked nociceptive activity in the trigeminocervical com-plex (TCC).
References	[1]. Eloisa Rubio-Beltrán, et al. PACAP38 and PAC1 receptor blockade: a new target for headache? J Headache Pain. 2018 Aug 7;19(1):64. [2]. Hoffmann J, et al. PAC-1 receptor antibody modulates nociceptive trigeminal activity in rat. Cephalalgia. 2016;36(1S):141–141.

No Any Chemical & Physical Properties

Shanghai Nianxing Industrial Co., Ltd
China
Product Name: Zelminemab (anti-PAC1)
Price: Click To Check
Purity: 95.0%
Delivery: 10 Day
Contact: Yang
Email: sales@echemcloud.com

Get all suppliers and price by the below link:

Zelminemab suppliers

Zelminemab price